# Treatment of Rett Syndrome With rhIGF-1 (Mecasermin [rDNA]Injection)

> **NCT01253317** · PHASE1 · COMPLETED · sponsor: **Boston Children's Hospital** · enrollment: 12 (actual)

## Conditions studied

- Rett Syndrome

## Interventions

- **DRUG:** rhIGF-1

## Key facts

- **NCT ID:** NCT01253317
- **Lead sponsor:** Boston Children's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12
- **Primary completion:** 2012-09
- **Final completion:** 2013-01
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2017-06-22

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01253317

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01253317, "Treatment of Rett Syndrome With rhIGF-1 (Mecasermin [rDNA]Injection)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01253317. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*